Michael Grey Net Worth

The estimated Net Worth of Michael G Grey is at least $7.45 Million dollars as of 28 September 2023. Mr. Grey owns over 20,000 units of Mirum Pharmaceuticals Inc stock worth over $1,649,620 and over the last 19 years he sold MIRM stock worth over $134,435. In addition, he makes $5,662,400 as Chairman of the Board at Mirum Pharmaceuticals Inc.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

or

Sign up with Google Sign up with Facebook

Mr. Grey MIRM stock SEC Form 4 insiders trading

Michael has made over 28 trades of the Mirum Pharmaceuticals Inc stock since 2008, according to the Form 4 filled with the SEC. Most recently he exercised 20,000 units of MIRM stock worth $319,200 on 28 September 2023.

The largest trade he's ever made was exercising 30,000 units of Mirum Pharmaceuticals Inc stock on 11 December 2013 worth over $651,300. On average, Michael trades about 3,491 units every 66 days since 2005. As of 28 September 2023 he still owns at least 39,361 units of Mirum Pharmaceuticals Inc stock.

You can see the complete history of Mr. Grey stock trades at the bottom of the page.

Michael Grey biography

Michael G. Grey serves as Chairman of the Board of the Company. Mr. Grey previously served as our Executive Chairman from March 2019 to December 2019 and as our Chief Executive Officer from our inception in May 2018 to March 2019. Mr. Grey has served as Executive Chairman of Amplyx Pharmaceuticals, Inc. (“Amplyx”), a pharmaceutical company, since January 2017; Reneo Pharmaceuticals, Inc. (“Reneo”), a pharmaceutical company, since December 2017; and Spruce Biosciences, Inc. (“Spruce Biosciences”), a biotechnology company, since April 2017. He has also served as a venture partner at Pappas Ventures, a venture capital firm, since January 2010 and as a director of Curzion Pharmaceuticals, Inc. (“Curzion”), a pharmaceutical company, since January 2019. Mr. Grey served from January 2019 to September 2019 as President and Chief Executive Officer of Curzion, from October 2015 to January 2017 as President and Chief Executive Officer of Amplyx, and from September 2014 to December 2017 as Chairman and Chief Executive Officer of Reneo. From February 2011 to June 2014, Mr. Grey served as President and Chief Executive Officer of Lumena Pharmaceuticals, Inc. (“Lumena”), which was acquired by Shire plc in June 2014. Mr. Grey has more than 45 years of experience in the pharmaceutical and biotechnology industries and has held senior positions at a number of companies, including President and Chief Executive Officer of SGX Pharmaceuticals, Inc. (sold to Eli Lilly and Company in 2008), President and Chief Executive Officer of Trega Biosciences, Inc. (sold to LION Bioscience, Inc. in 2001) and President of BioChem Therapeutic Inc. Prior to these, Mr. Grey served in various roles with Glaxo, Inc. and Glaxo Holdings PLC, culminating in his position as Vice President, Corporate Development and director of international licensing. Mr. Grey also serves on the boards of directors of BioMarin Pharmaceutical Inc., Horizon Therapeutics Public Limited Company and Mirati Therapeutics Inc., each public biotechnology companies.

What is the salary of Michael Grey?

As the Chairman of the Board of Mirum Pharmaceuticals Inc, the total compensation of Michael Grey at Mirum Pharmaceuticals Inc is $5,662,400. There are 1 executives at Mirum Pharmaceuticals Inc getting paid more, with Christopher Peetz having the highest compensation of $6,235,180.

How old is Michael Grey?

Michael Grey is 67, he's been the Chairman of the Board of Mirum Pharmaceuticals Inc since 2020. There are no older and 19 younger executives at Mirum Pharmaceuticals Inc.

What's Michael Grey's mailing address?

Michael's mailing address filed with the SEC is C/O MIRUM PHARMACEUTICALS, INC., 989 E HILLSDALE BLVD., SUITE 300, FOSTER CITY, CA, 94404.

Insiders trading at Mirum Pharmaceuticals Inc

Over the last 5 years, insiders at Mirum Pharmaceuticals Inc have traded over $10,912,565 worth of Mirum Pharmaceuticals Inc stock and bought 7,735,045 units worth $117,972,829 . The most active insiders traders include Forest Baskett, Scott D Sandell, and Anthony A. Jr. Florence. On average, Mirum Pharmaceuticals Inc executives and independent directors trade stock every 24 days with the average trade being worth of $4,538,937. The most recent stock trade was executed by Patrick J Heron on 6 September 2024, trading 230 units of MIRM stock currently worth $9,563.

What does Mirum Pharmaceuticals Inc do?

mirum pharmaceuticals, inc., a biopharmaceutical company, focuses on the development and commercialization of a late-stage pipeline of novel therapies for debilitating liver diseases. its lead product candidate is maralixibat, an investigational oral drug that is in phase 3 clinical trial for the treatment of progressive familial intrahepatic cholestasis disease, as well as for the treatment of alagille syndrome and biliary atresia disease. the company is also develops volixibat drug for treatment of intrahepatic cholestasis of pregnancy and primary sclerosing cholangitis. mirum pharmaceuticals, inc. was founded in 2018 and is headquartered in foster city, california.

Complete history of Mr. Grey stock trades at Biomarin Pharmaceutical, Horizon Therapeutics Plc, Mirati Therapeutics Inc, Mirum Pharmaceuticals Inc, and Spruce Biosciences

Mirum Pharmaceuticals Inc executives and stock owners

Mirum Pharmaceuticals Inc executives and other stock owners filed with the SEC include:

• Christopher Peetz,
  President, Chief Executive Officer, Director
• Michael Grey,
  Chairman of the Board
• Lara Longpre,
  Chief Development Officer
• Pamela Vig,
  Chief Scientific Officer
• Christopher Peetz,
  Pres, CEO & Director
• Dr. Ian Clements,
  Chief Financial Officer
• Peter Radovich M.B.A., Ph.D.,
  Chief Operating Officer
• Laurent Fischer,
  Independent Director
• Laura Brege,
  Independent Director
• Niall ODonnell,
  Independent Director
• Edward Mathers,
  Independent Director
• Patrick Heron,
  Independent Director
• Tiba Aynechi,
  Director
• Edwin Tucker,
  Chief Medical Officer
• Ian Clements,
  Chief Financial Officer
• Vinita P. Kumar,
  Sr. vice Pres of Quality
• Lara Longpre MBA, MSC,
  Chief Devel. Officer
• Dr. Pamela Vig Ph.D.,
  Head of R&D
• Erin Campany,
  Sr. VP of HR
• Dr. Edwin Jonathan Tucker M.D.,
  Chief Medical Officer
• Paul K. Ross,
  Chief Compliance Officer
• Lara Longpre MSC, MBA,
  Chief Devel. Officer
• Carol L Brosgart,
  Director
• Holdings A/S Novo,
  10% owner
• Mohamad Makhzoumi,
  10% owner
• Niall O'donnell,
  Director
• Peter W. Sonsini,
  10% owner
• Anthony A. Jr. Florence,
  10% owner
• Ali Behbahani,
  10% owner
• Forest Baskett,
  10% owner
• Joshua Makower,
  10% owner
• David M Mott,
  10% owner
• Paul Edward Walker,
  10% owner
• Life Sciences Ix, L.P.Fhmls...,
  
• Carmen Chang,
  10% owner
• Scott D Sandell,
  10% owner
• Peter J Barris,
  10% owner
• Enterprise Associates 16, L...,
  
• James E Deerfield Mgmt Hif,...,
  
• Enterprise Associates 16, L...,
  10% owner
• William Fairey,
  
• Timothy P Walbert,
  
• Joanne Quan,
  CHIEF MEDICAL OFFICER
• Saira Ramasastry,
  
• James E Deerfield Mgmt Hif,...,
  
• Lon Cardon,
  
• Partners 16, L.P.Nea 16 Gp,...,
  
• Jolanda Howe,
  SVP, GLOBAL CONTROLLER
• Eric Bjerkholt,
  CHIEF FINANCIAL OFFICER
• Peter Radovich,
  PRESIDENT AND COO